Table 6.
Incremental cost-effectiveness ratio (ICER) value between the two groups.
| Parameters | Newer AED group | Conventional AED group | Difference | Incremental cost-effectiveness ratio |
|---|---|---|---|---|
| The total cost of treatment in USD | 104.77 | 44.04 | 60.73 | |
| Improvement in QOLIE-10 mean scores at the end of the study as compared to enrolment | 0.58(2.42–1.84) | 0.48(2.33–1.85) | 0.1 | 60.73/0.1 = 607.3# |
| Improvement in PSQI median scores at end of study as compared to enrolment | 2(4–2) | 1(3–2) | 1 | 60.73# |
| Improvement in LAEP mean scores at the end of the study as compared to enrolment | 4.5(32.1–27.91) | 2.19(30.72–28.53) | 2.31 | 60.73/2.31 = 26.29# |
| Improvement in GIQLI mean scores at the end of the study as compared to enrolment | −11.1*(119.75–130.85) | −6.51*(124.27–130.78) | 4.59 | 60.73/4.59 = 13.23# |
| % change in seizure frequency in 6 months duration | 60.29 | 53.06 | 7.23 | 60.73/7.23 = 8.39# |
*
depicts improvement in GIQLI score between 0 and 6 months follow up period.
#
added cost for newer AEDs to improve the parameter by one unit as compared to conventional AEDs. AEDs: Antiepileptic drugs; QOLIE-10: Patient weighted Quality of life Index in epilepsy; PSQI: Pittsburgh Sleep Quality Index; GIQLI: Gastrointestinal Quality of life Index; LAEP: Liverpool Adverse effect profile